Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2019, Article ID 1780567, 11 pages
https://doi.org/10.1155/2019/1780567
Research Article

Enhancement of the Soluble Form of OX40 and OX40L Costimulatory Molecules but Reduction of the Membrane Form in Type 1 Diabetes (T1D)

1Jiangsu Institute of Clinical Immunology, First Affiliated Hospital of Soochow University, Suzhou, China
2Institute of Blood and Marrow Transplantation, First Affiliated Hospital of Soochow University, Suzhou, China
3Jiangsu Key Laboratory of Clinical Immunology, First Affiliated Hospital of Soochow University, Suzhou, China
4Department of Endocrinology, Second Affiliated Hospital of Soochow University, Suzhou, China

Correspondence should be addressed to Chen Fang; moc.anis@1199afa and Cuiping Liu; moc.621@0891gnipiucuil

Received 12 December 2018; Revised 15 May 2019; Accepted 28 June 2019; Published 1 August 2019

Academic Editor: Ravirajsinh N. Jadeja

Copyright © 2019 Jingnan An et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Battaglia, L. Nigi, and F. Dotta, “Towards an earlier and timely diagnosis of type 1 diabetes: is it time to change criteria to define disease onset?” Current Diabetes Reports, vol. 15, no. 12, p. 115, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. W. Łuczyński, A. Stasiak-Barmuta, A. Juchniewicz et al., “The mRNA expression of pro- and anti-inflammatory cytokines in T regulatory cells in children with type 1 diabetes,” Folia Histochemica et Cytobiologica, vol. 48, no. 1, pp. 93–100, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. J. A. Janzen Claude, H. D. Hadjistavropoulos, and L. Friesen, “Exploration of health anxiety among individuals with diabetes: prevalence and implications,” Journal of Health Psychology, vol. 19, no. 2, pp. 312–322, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. F. Zouidi, M. Stayoussef, D. Bouzid et al., “Contribution of PTPN22, CD28, CTLA-4 and ZAP-70 variants to the risk of type 1 diabetes in Tunisians,” Gene, vol. 533, no. 1, pp. 420–426, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. M. L. Colli, J. L. E. Hill, L. Marroquí et al., “PDL1 is expressed in the islets of people with type 1 diabetes and is up-regulated by interferons-α and-γ via IRF1 induction,” EBioMedicine, vol. 36, pp. 367–375, 2018. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Momin, S. Flores, B. Angel B, E. Codner D, E. Carrasco P, and F. Perez-Bravo, “Interactions between programmed death 1 (PD-1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) gene polymorphisms in type 1 diabetes,” Diabetes Research and Clinical Practice, vol. 83, no. 3, pp. 289–294, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. B. Nambam and M. J. Haller, “Updates on immune therapies in type 1 diabetes,” European Endocrinology, vol. 12, no. 2, pp. 89–95, 2016. View at Publisher · View at Google Scholar · View at Scopus
  8. T. Orban, B. Bundy, D. J. Becker et al., “Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial,” The Lancet, vol. 378, no. 9789, pp. 412–419, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Orban, B. Bundy, D. J. Becker et al., “Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment,” Diabetes Care, vol. 37, no. 4, pp. 1069–1075, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. W. Lei, D. Zeng, G. Liu et al., “Crucial role of OX40/OX40L signaling in a murine model of asthma,” Molecular Medicine Reports, vol. 17, no. 3, pp. 4213–4220, 2018. View at Publisher · View at Google Scholar · View at Scopus
  11. G. J. Webb, G. M. Hirschfield, and P. J. L. Lane, “OX40, OX40L and autoimmunity: a comprehensive review,” Clinical Reviews in Allergy & Immunology, vol. 50, no. 3, pp. 312–332, 2016. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Karulf, A. Kelly, A. D. Weinberg, and J. A. Gold, “OX40 ligand regulates inflammation and mortality in the innate immune response to sepsis,” The Journal of Immunology, vol. 185, no. 8, pp. 4856–4862, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. W. Lei, D. X. Zeng, C. H. Zhu et al., “The upregulated expression of OX40/OX40L and their promotion of T cells proliferation in the murine model of asthma,” Journal of Thoracic Disease, vol. 6, no. 7, pp. 979–987, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. M. M. Cavanagh and T. Hussell, “Is it wise to target the late costimulatory molecule OX40 as a therapeutic target?” Archivum Immunologiae et Therapiae Experimentalis, vol. 56, no. 5, pp. 291–297, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Irie, Y. Wu, K. Kachapati, R. S. Mittler, and W. M. Ridgway, “Modulating protective and pathogenic CD4+ subsets via CD137 in type 1 diabetes,” Diabetes, vol. 56, no. 1, pp. 186–196, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. D. J. Lenschow, S. C. Ho, H. Sattar et al., “Differential effects of anti-b7-1 and anti-b7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse,” Journal of Experimental Medicine, vol. 181, no. 3, pp. 1145–1155, 1995. View at Publisher · View at Google Scholar · View at Scopus
  17. C. S. Haddad, P. Bhattacharya, K. Alharshawi et al., “Age-dependent divergent effects of OX40L treatment on the development of diabetes in nod mice,” Autoimmunity, vol. 49, no. 5, pp. 298–311, 2016. View at Publisher · View at Google Scholar · View at Scopus
  18. R. W. Beck, W. V. Tamborlane, R. M. Bergenstal et al., “The T1D exchange clinic registry,” The Journal of Clinical Endocrinology & Metabolism, vol. 97, no. 12, pp. 4383–4389, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. M. L. Ford, A. B. Adams, and T. C. Pearson, “Targeting co-stimulatory pathways: transplantation and autoimmunity,” Nature Reviews Nephrology, vol. 10, no. 1, pp. 14–24, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. G. P. Doss, G. Agoramoorthy, and C. Chakraborty, “TNF/TNFR: drug target for autoimmune diseases and immune-mediated inflammatory diseases,” Frontiers in Bioscience, vol. 19, no. 7, pp. 1028–1040, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. D. H. Wagner Jr., “Overlooked mechanisms in type 1 diabetes etiology: how unique costimulatory molecules contribute to diabetogenesis,” Frontiers in Endocrinology, vol. 8, p. 208, 2017. View at Publisher · View at Google Scholar · View at Scopus
  22. T. Maj, S. Wei, T. Welling, and W. Zou, “T cells and costimulation in cancer,” The Cancer Journal, vol. 19, no. 6, pp. 473–482, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Bour-Jordan and J. A. Bluestone, “Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells,” Immunological Reviews, vol. 229, no. 1, pp. 41–66, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. G. Zhang, J. Hou, J. Shi, G. Yu, B. Lu, and X. Zhang, “Soluble CD276 (B7-H3) is released from monocytes, dendritic cells and activated t cells and is detectable in normal human serum,” Immunology, vol. 123, no. 4, pp. 538–546, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. X. Hu, J. Wu, J. An et al., “Development of a novel monoclonal antibody to human inducible co-stimulator ligand (ICOSL): biological characteristics and application for enzyme-linked immunosorbent assay,” International Immunopharmacology, vol. 36, pp. 151–157, 2016. View at Publisher · View at Google Scholar · View at Scopus
  26. G. Magistrelli, P. Jeannin, N. Herbault et al., “A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells,” European Journal of Immunology, vol. 29, no. 11, pp. 3596–3602, 1999. View at Publisher · View at Google Scholar
  27. C. Nielsen, L. Ohm-Laursen, T. Barington, S. Husby, and S. T. Lillevang, “Alternative splice variants of the human PD-1 gene,” Cellular Immunology, vol. 235, no. 2, pp. 109–116, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Ilzecka, “Serum soluble OX40 in patients with amyotrophic lateral sclerosis,” Acta Clinica Croatica, vol. 51, no. 1, pp. 3–7, 2012. View at Google Scholar
  29. L. Taylor and H. Schwarz, “Identification of a soluble OX40 isoform: development of a specific and quantitative immunoassay,” Journal of Immunological Methods, vol. 255, no. 1-2, pp. 67–72, 2001. View at Publisher · View at Google Scholar · View at Scopus
  30. W. Lei, C. H. Zhu, X. W. Q. Zeng da et al., “SOX40L: an important inflammatory mediator in adult bronchial asthma,” Annals of the Academy of Medicine, Singapore, vol. 41, no. 5, pp. 200–204, 2012. View at Google Scholar
  31. J. Yan, J. Gong, G. Chen, P. Liu, C. Wang, and P. Yang, “Evaluation of serum soluble OX40 ligand as a prognostic indicator in acute coronary syndrome patients,” Clinica Chimica Acta, vol. 411, no. 21-22, pp. 1662–1665, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. J. K. Laustsen, T. K. Rasmussen, K. Stengaard-Pedersen et al., “Soluble OX40L is associated with presence of autoantibodies in early rheumatoid arthritis,” Arthritis Research & Therapy, vol. 16, no. 5, p. 474, 2014. View at Publisher · View at Google Scholar · View at Scopus
  33. W. Qin, W. Hongya, C. Yongjing et al., “Increased OX40 and soluble OX40 ligands in children with Henoch-Schonlein purpura: association with renal involvement,” Pediatric Allergy and Immunology, vol. 22, no. 1, Part I, pp. 54–59, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. J. M. Wenzlau and J. C. Hutton, “Novel diabetes autoantibodies and prediction of type 1 diabetes,” Current Diabetes Reports, vol. 13, no. 5, pp. 608–615, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. L. Yu, Z. Zhao, and A. K. Steck, “T1D autoantibodies: room for improvement?” Current Opinion in Endocrinology & Diabetes and Obesity, vol. 24, no. 4, pp. 285–291, 2017. View at Publisher · View at Google Scholar · View at Scopus
  36. V. Lampasona and D. Liberati, “Islet autoantibodies,” Current Diabetes Reports, vol. 16, no. 6, p. 53, 2016. View at Publisher · View at Google Scholar · View at Scopus
  37. G. Fousteri, E. Ippolito, R. Ahmed, and A. Rahim Hamad, “Beta-cell specific autoantibodies: are they just an indicator of type 1 diabetes?” Current Diabetes Reviews, vol. 13, no. 3, pp. 322–329, 2017. View at Publisher · View at Google Scholar · View at Scopus
  38. A. Lounici Boudiaf, D. Bouziane, M. Smara et al., “Could ZnT8 antibodies replace ICA, GAD, IA2 and insulin antibodies in the diagnosis of type 1 diabetes?” Current Research in Translational Medicine, vol. 66, no. 1, pp. 1–7, 2018. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Mauer and A. Doria, “Uric acid and diabetic nephropathy risk,” Contributions to Nephrology, vol. 192, pp. 103–109, 2018. View at Publisher · View at Google Scholar · View at Scopus
  40. P. Hovind, P. Rossing, L. Tarnow, R. J. Johnson, and H. H. Parving, “Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study,” Diabetes, vol. 58, no. 7, pp. 1668–1671, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. Y. Huang, S. C. Li, J. Hu et al., “Gut microbiota profiling in Han Chinese with type 1 diabetes,” Diabetes Research and Clinical Practice, vol. 141, pp. 256–263, 2018. View at Publisher · View at Google Scholar · View at Scopus
  42. D. Ruiz-Aranda, L. Zysberg, E. García-Linares, A. M. Castellano-Guerrero, M. A. Martínez-Brocca, and M. R. Gutiérrez-Colosía, “Emotional abilities and HbA1c levels in patients with type 1 diabetes,” Psychoneuroendocrinology, vol. 93, pp. 118–123, 2018. View at Publisher · View at Google Scholar · View at Scopus
  43. K. Nirantharakumar, N. Mohammed, K. A. Toulis, G. N. Thomas, and P. Narendran, “Clinically meaningful and lasting HbA1c improvement rarely occurs after 5 years of type 1 diabetes: an argument for early, targeted and aggressive intervention following diagnosis,” Diabetologia, vol. 61, no. 5, pp. 1064–1070, 2018. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Szypowska, A. Stelmaszczyk-Emmel, U. Demkow, and W. Łuczyński, “High expression of OX40 (CD134) and 4-1BB (CD137) molecules on CD4+CD25high cells in children with type 1 diabetes,” Advances in Medical Sciences, vol. 59, no. 1, pp. 39–43, 2014. View at Publisher · View at Google Scholar · View at Scopus
  45. D. Bresson, G. Fousteri, Y. Manenkova, M. Croft, and M. von Herrath, “Antigen-specific prevention of type 1 diabetes in NOD mice is ameliorated by OX40 agonist treatment,” Journal of Autoimmunity, vol. 37, no. 4, pp. 342–351, 2011. View at Publisher · View at Google Scholar · View at Scopus